2022 Fiscal Year Final Research Report
Development of novel tumor-targeting nanoparticles for malignant brain tumor neutron capture therapy and diagnosis
| Project/Area Number |
20K07672
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中井 啓 筑波大学, 医学医療系, 准教授 (50436284)
鶴淵 隆夫 筑波大学, 医学医療系, 講師 (70778901)
MATHIS BRYAN 筑波大学, 附属病院, 病院講師 (80794635)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | BNCT / glioma / nanoparticles / boron / gold / dosimetry / tumor targeting / liposomes |
|---|
| Outline of Final Research Achievements |
Novel complex boron nanoparticles (BNPs) for boron neutron capture therapy (BNCT) have been developed. BNPs showed low toxicity, more prolonged accumulation in the tumor cells, and a more prominent irradiation effect than currently used boronophenylalanine (BPA). Tumor-targeting ligand has also been synthesized. Using new calculation methods, the absorbed dose evaluation based on gold activation after neutron irradiation was done. Due to difficulties in the covalent binding of boron and gold, a liposome-based structure was used to couple both critical elements. Irradiation of larger animals (cats and dogs) with spontaneous tumors was also done to study the technical aspects of BNCT close to actual clinical conditions.
|
| Free Research Field |
radiation oncology
|
| Academic Significance and Societal Importance of the Research Achievements |
With the development of accelerators for BNCT, there is a need for new, more effective boron compounds with absorbed dose estimation to improve cancer therapy. Our complex nanoparticles providing therapy and diagnosis will help further BNCT development and clinical application worldwide.
|
